Allergan gets FDA approval for oral migraine treatment

Allergan (AGN +0.5%) gets U.S. FDA approval for Ubrelvey (ubrogepant) for the acute treatment of migraine with or without aura in adults.

Ubrelvy is the first orally administered calcitonin gene-related peptide receptor antagonist for the treatment of migraines once they start, Allergan says.

Previously: FDA accepts Allergan application for migraine med ubrogepant (March 11)

https://seekingalpha.com/news/3528262-allergan-gets-fda-approval-for-oral-migraine-treatment